Business

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review

articleDizal (jiangsu) Pharmaceutical Co. Ltd. Class AMay 27, 20263/news/announcement-on-voluntary-disclosure-of-the-acceptance-of-the-new-drug-application-for-sunvozertinib-as-first-line-monotherapy-for-egfr-exon20ins-non-small-cell-lung-cancer-by-the-national-medical-products-administration-and-its-inclusion-in-priority-review
Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A